万泰生物：疫苗板块受行业政策调整及市场竞争等因素影响短期销售承压

Core Viewpoint - The company has experienced a decline in revenue and losses for three consecutive quarters, primarily due to industry policy adjustments and market competition affecting its vaccine segment, as well as government price reductions impacting its IVD segment [1] Group 1: Company Performance - The vaccine segment is under pressure from industry policy changes and increased market competition, leading to a significant year-on-year decline in revenue and profit [1] - The IVD segment is affected by government procurement price cuts and the unbundling of testing packages, which will require time to stabilize before performance improves [1] - Both segments are contributing to a temporary impact on the company's overall net profit [1]